MK-677 vs Ipamorelin
MK-677 is an oral non-peptide ghrelin mimetic with 24-hour GH elevation; Ipamorelin is an injectable GHRP with selective, pulsatile GH release and fewer side effects.
Last updated: 2026-03-08
MK-677 (Ibutamoren) and Ipamorelin are two of the most discussed growth hormone secretagogues in research, but they are fundamentally different compounds. MK-677 is a non-peptide ghrelin receptor agonist that can be taken orally and produces sustained GH elevation over 24 hours. Ipamorelin is a pentapeptide GHRP (growth hormone-releasing peptide) that produces clean, pulsatile GH release with minimal impact on other hormones.
This comparison matters because the choice between sustained versus pulsatile GH elevation has significant implications for efficacy, side effects, and long-term safety — particularly regarding insulin sensitivity, cortisol, and prolactin.
**Important Note:** Neither MK-677 nor Ipamorelin is approved for therapeutic use by the MHRA, EMA, or FDA. MK-677 has undergone extensive clinical trials but has not received regulatory approval. This comparison is for educational purposes only.
Quick Comparison Table
| Category | MK-677 | Ipamorelin |
|---|---|---|
| Chemical Class | Non-peptide ghrelin receptor agonist (growth hormone secretagogue) | Pentapeptide growth hormone-releasing peptide (GHRP) |
| Molecular Weight | 528.7 Da (small molecule) | 711.9 Da (pentapeptide) |
| Administration | Oral (unique advantage — survives GI tract) | Subcutaneous or intravenous injection |
| GH Release Pattern | Sustained elevation over 24 hours | Pulsatile release mimicking natural GH secretion |
| Half-Life | ~4-6 hours (but effects persist 24h) | ~2 hours |
| Cortisol Impact | No significant increase | No significant increase (selective) |
| Prolactin Impact | No significant increase | No significant increase (selective) |
| Appetite Stimulation | Marked increase (ghrelin pathway) | Minimal to none |
| Insulin Sensitivity | May impair (documented concern in trials) | Minimal impact on insulin sensitivity |
| Human Trials | Extensive Phase II data (multiple indications) | Limited clinical data |
| Regulatory Status | Investigational — not approved | Research compound only |
How They Work: Mechanism of Action
MK-677
MK-677 (Ibutamoren) Mechanism:
MK-677 is a non-peptide ghrelin receptor agonist (growth hormone secretagogue receptor, GHS-R1a). Its mechanism is fundamentally different from traditional peptide GHRPs:
1. **Ghrelin Receptor Activation** MK-677 mimics the endogenous hunger hormone ghrelin by binding to GHS-R1a receptors in the pituitary and hypothalamus. This stimulates GH secretion from somatotroph cells in a dose-dependent manner.
2. **Sustained GH Elevation** Unlike pulsatile GHRPs, MK-677's oral bioavailability and pharmacokinetics produce sustained GH elevation over 24 hours from a single daily dose. This raises both mean GH and IGF-1 levels to youthful ranges.
3. **Growth Hormone Axis Amplification** MK-677 increases GH pulsatility amplitude without significantly altering pulse frequency. It also increases IGF-1 through hepatic stimulation, creating a dual anabolic signal.
4. **Appetite Stimulation** Via ghrelin receptor activation in the hypothalamus, MK-677 stimulates appetite — a direct pharmacological effect of its mechanism, not a side effect.
5. **Sleep Architecture Effects** MK-677 enhances Stage IV (deep) sleep duration, likely through GH-mediated pathways. GH secretion is naturally concentrated during deep sleep.
Ipamorelin
Ipamorelin Mechanism:
Ipamorelin is a pentapeptide growth hormone-releasing peptide (GHRP) that binds to GHS-R1a with high selectivity:
1. **Selective GHS-R1a Agonism** Ipamorelin binds the ghrelin receptor but with a uniquely selective profile. Unlike GHRP-6 and GHRP-2, it does not stimulate ACTH, cortisol, or prolactin release at GH-stimulating doses. This selectivity is Ipamorelin's defining characteristic.
2. **Pulsatile GH Release** Ipamorelin produces acute GH pulses that peak within 30-40 minutes and return to baseline within 2-3 hours. This pattern more closely mimics the natural ultradian rhythm of GH secretion.
3. **Dose-Dependent, Ceiling-Limited Response** GH release from Ipamorelin is dose-dependent up to a ceiling, after which higher doses do not produce proportionally greater GH release. This built-in ceiling may contribute to its safety profile.
4. **Synergy with GHRH** Ipamorelin is often combined with CJC-1295 (a GHRH analogue) because GHRH and GHRP work through complementary pathways — GHRH initiates GH release while GHRPs amplify it. The combination produces greater GH release than either alone.
5. **GI Motility Effects** Ipamorelin has demonstrated prokinetic effects on the GI tract, accelerating bowel recovery in post-surgical patients — a mechanism independent of GH secretion.
Clinical Trial Evidence
MK-677 Clinical Studies
Participants: 32 adults
Duration: 4 days
MK-677 25mg daily increased mean 24h GH concentration by 97% and IGF-1 by 52% compared to placebo. GH pulsatility was preserved.
Demonstrated oral bioavailability and dose-dependent GH stimulation
Participants: 65 elderly adults (64-81y)
Duration: 12 months
MK-677 25mg daily increased GH and IGF-1 to young adult levels. Fat-free mass increased by 1.1kg vs placebo (p=0.003). However, fasting glucose increased by 0.3 mmol/L.
Longest MK-677 trial; confirmed anabolic effects but raised insulin sensitivity concerns
Participants: 161 elderly hip fracture patients
Duration: 6 months
MK-677 25mg improved functional measures (stair climbing, gait speed) versus placebo. No significant effect on bone mineral density at 6 months. Fasting glucose increased.
Functional benefit in recovery, but glycaemic concerns in vulnerable population
Participants: 7 young healthy males
Duration: 7 days
MK-677 25mg increased duration of Stage IV (deep) sleep by 50% and REM sleep by 20%. GH secretion during sleep was amplified.
Important sleep architecture benefit — unique among GH secretagogues
Participants: 24 obese postmenopausal women
Duration: 2 months
MK-677 25mg increased markers of bone formation (osteocalcin +26%) without affecting bone resorption markers. IGF-1 increased by 40%.
Suggests anabolic bone effects distinct from anti-resorptive therapies
Ipamorelin Clinical Studies
Participants: 6 healthy males
Duration: Single dose
Ipamorelin 1 mcg/kg IV produced a dose-dependent GH release peaking at ~35 ng/mL within 30 minutes. No change in cortisol, prolactin, FSH, LH, or TSH at any dose tested.
Established Ipamorelin's uniquely selective GH release profile
Participants: 24 healthy males (crossover)
Duration: Single dose comparison
Ipamorelin produced equivalent GH release to GHRP-6 without the cortisol (+21%) and prolactin (+56%) increases seen with GHRP-6. ACTH was unaffected by Ipamorelin.
Confirmed Ipamorelin as the most selective GHRP — critical differentiator
Participants: 114 patients post-abdominal surgery
Duration: 7 days post-op
Ipamorelin 0.03 mg/kg IV three times daily reduced time to first bowel movement by ~23 hours versus placebo (p=0.003). GI recovery was significantly accelerated.
Demonstrated therapeutic application beyond GH secretion
Participants: 8 healthy males
Duration: 8 days (multiple dosing)
Repeated subcutaneous Ipamorelin (1 mcg/kg three times daily) maintained GH release without significant desensitisation over the study period. No tachyphylaxis observed.
Important for chronic use potential — no loss of efficacy with repeated dosing
Participants: Female rats (ovariectomised model)
Duration: 12 weeks
Ipamorelin 0.1 mg/kg daily prevented ovariectomy-induced bone loss and increased bone formation rate by 30%. Cortical bone thickness was preserved.
Preclinical bone data supporting potential anti-osteoporotic effects via GH pathway
Benefits Comparison
MK-677 Unique Benefits
- Oral administration — no injections required
- 24-hour sustained GH and IGF-1 elevation from single daily dose
- Extensive human clinical trial data across multiple populations
- Significant sleep quality improvement (increased deep sleep by 50%)
- Appetite stimulation (beneficial for underweight/sarcopenic patients)
- 12-month safety data available in elderly populations
- Anabolic bone formation effects documented in human trials
Shared Benefits
- Stimulate endogenous GH secretion (preserve feedback regulation)
- Increase IGF-1 levels
- Do not suppress cortisol or prolactin (both are selective in this regard)
- Potential body composition benefits (increased lean mass, reduced fat)
- Potential bone density support through GH/IGF-1 pathway
- Generally well-tolerated in research settings
- Do not require exogenous GH — stimulate the body's own production
Ipamorelin Unique Benefits
- Most selective GHRP — no cortisol, prolactin, or ACTH increase
- Clean pulsatile GH release mimicking natural physiology
- Minimal appetite stimulation (advantage for those not wanting weight gain)
- Better insulin sensitivity profile than MK-677
- No desensitisation with repeated dosing (maintained efficacy)
- Gut motility benefits (demonstrated in post-surgical recovery)
- Often combined with CJC-1295 for synergistic GHRH+GHRP effects
Research & Evidence
MK-677 Research
MK-677 Research Evidence:
MK-677 has one of the most extensive clinical research programmes of any investigational GH secretagogue, with studies spanning over two decades.
Key Findings: - Reliable, dose-dependent GH and IGF-1 elevation from 10-50mg oral doses - 12-month safety data in elderly showing sustained anabolic effects - Sleep architecture improvement (unique benefit among secretagogues) - Bone turnover marker improvements in postmenopausal women - Functional recovery benefits in hip fracture patients
Concerns: - Consistent finding of increased fasting glucose and reduced insulin sensitivity - The insulin resistance effect is dose-dependent and may limit use in metabolically vulnerable populations (elderly, obese, prediabetic) - Despite extensive Phase II data, no regulatory approval has been granted — partly due to the insulin sensitivity signal
Ipamorelin Research
Ipamorelin Research Evidence:
Ipamorelin's research is more limited in volume but notable for consistently demonstrating its selectivity advantage.
Key Findings: - Uniquely selective GH release without cortisol, prolactin, or ACTH elevation - No desensitisation with repeated dosing (8-day confirmed) - Therapeutic effect in post-operative ileus (accelerated bowel recovery) - Dose-response is predictable and reproducible - Well-tolerated across all published studies
Limitations: - Fewer published human studies than MK-677 - No long-term (>1 month) human data - No large Phase II/III efficacy trials for body composition - Injectable only — no oral formulation possible
Head-to-Head Analysis
Direct Comparison:
No head-to-head clinical trial has compared MK-677 and Ipamorelin directly. However, the mechanistic and clinical profiles allow meaningful comparison:
GH Release Pattern: MK-677 produces sustained 24-hour GH elevation, which differs from natural pulsatile GH secretion. Ipamorelin produces discrete GH pulses that more closely mimic physiology. The clinical significance of this difference is debated — some researchers argue pulsatile release is more effective for anabolism, while sustained elevation may be adequate for IGF-1 maintenance.
Safety Profile: Ipamorelin has a cleaner safety profile. MK-677's insulin sensitivity impairment is its most significant liability and has likely contributed to its failure to gain regulatory approval despite extensive human data.
Practical Considerations: MK-677's oral availability is a major practical advantage. Ipamorelin requires injection, though it's often combined with CJC-1295 DAC for less frequent dosing.
Protocol Comparison
MK-677 Protocol
MK-677 Research Protocols:
Dosing: Clinical trials have consistently used 25mg daily as the standard dose. Some studies examined 10mg and 50mg. The 25mg dose provides near-maximal GH stimulation with acceptable tolerability.
Administration: Oral capsule, typically taken once daily in the evening (to align with natural nocturnal GH secretion and leverage sleep quality benefits).
Duration: Studies range from single-dose to 12 months. Most anabolic effects become apparent after 2-4 weeks. Sleep benefits are noticeable within days.
Monitoring: Fasting glucose and insulin should be monitored due to the documented insulin sensitivity concern. HbA1c at baseline and periodic intervals is recommended.
⚠️ Disclaimer: MK-677 is not approved for human use. These protocols reflect clinical trial designs, not treatment recommendations.
Ipamorelin Protocol
Ipamorelin Research Protocols:
Dosing: Clinical studies used 1 mcg/kg IV or subcutaneous. Common research doses cited are 200-300 mcg per injection, administered 2-3 times daily (aligning with natural GH pulse frequency).
Administration: Subcutaneous injection, typically in the abdomen. Often co-administered with CJC-1295 (modified GRF 1-29) for synergistic GHRH+GHRP stimulation.
Timing: Best administered on an empty stomach (GH release is blunted by recent food intake, particularly carbohydrates and fats). Common timing: morning fasted, pre-workout, and before bed.
Duration: No long-term human studies establish optimal cycle length. Research protocols range from single-dose to several weeks.
⚠️ Disclaimer: Ipamorelin is not approved for human use. These protocols reflect clinical trial designs, not treatment recommendations.
Combined Use
Theoretical MK-677 + Ipamorelin Combination:
While both are GH secretagogues, they work through different receptor pathways: - MK-677: Ghrelin receptor (GHS-R1a) — sustained activation - Ipamorelin: GHRP receptor — pulsatile stimulation
Theoretical Rationale: Some researchers have explored using Ipamorelin for acute GH pulse amplification alongside lower-dose MK-677 for baseline IGF-1 elevation. The different receptor mechanisms suggest additive rather than competitive effects.
Concerns: - No published data on the combination - Combined GH elevation could worsen insulin sensitivity more than either alone - May be redundant — both ultimately stimulate pituitary GH release - Risk of exceeding physiological GH levels with unknown long-term consequences
⚠️ Combined use is entirely experimental with no scientific validation.
Safety Profiles
MK-677 Safety
MK-677 Safety Profile:
Based on clinical trials involving hundreds of participants:
Common side effects: - Increased appetite (very common — ghrelin pathway mediated) - Water retention and mild oedema (dose-dependent) - Transient muscle pain (usually resolves within weeks) - Drowsiness/lethargy (some users; may relate to GH-mediated sleep changes)
Significant concerns: - Insulin resistance: Consistently documented across trials. Fasting glucose increases of 0.3-0.5 mmol/L. This is MK-677's most important safety limitation and may preclude use in prediabetic or diabetic individuals. - Potential to worsen existing type 2 diabetes or metabolic syndrome - Theoretical concern about prolonged IGF-1 elevation and cancer risk (not observed in trials up to 12 months, but long-term data is lacking)
Contraindications (theoretical): - Type 2 diabetes or insulin resistance - Active malignancy - Uncontrolled hypertension (fluid retention)
Ipamorelin Safety
Ipamorelin Safety Profile:
Based on available clinical data:
Common side effects: - Injection site reactions (mild, transient) - Transient flushing or warmth post-injection - Mild headache (uncommon)
Safety advantages: - No cortisol increase — unlike GHRP-6 and GHRP-2 - No prolactin increase — preserves reproductive hormone balance - No significant appetite stimulation — unlike MK-677 and GHRP-6 - No documented insulin sensitivity impairment — critical advantage over MK-677 - No desensitisation with repeated use
Limitations: - Less long-term human safety data than MK-677 - Injectable administration carries inherent risks (infection, injection site issues) - Like all GH-elevating compounds, theoretical concern about prolonged IGF-1 elevation
Ipamorelin's selectivity makes it the best-tolerated GHRP in its class.
The Verdict: When to Choose Which?
Choose MK-677 When:
- When oral administration is strongly preferred (needle-averse individuals)
- When sustained 24-hour GH/IGF-1 elevation is the research goal
- When sleep quality improvement is a primary objective
- When appetite stimulation is desired (sarcopenia, underweight)
- When wanting the most extensively studied GH secretagogue (human data)
Choose Ipamorelin When:
- When insulin sensitivity must be preserved (metabolic health priority)
- When clean, selective GH release is desired (no cortisol/prolactin effects)
- When appetite stimulation is unwanted (body composition focus)
- When combining with CJC-1295 for synergistic GHRH+GHRP protocols
- When pulsatile GH release (mimicking natural physiology) is preferred
- When tolerability and side effect minimisation are priorities
Consider Combining When:
- Theoretical combination for dual-pathway GH amplification
- No published research supports the combination
- Risk of compounding insulin sensitivity effects from excessive GH elevation
- Generally, choosing one or the other is more prudent than combining
Frequently Asked Questions
Conclusion
MK-677 and Ipamorelin represent two fundamentally different approaches to stimulating endogenous growth hormone. MK-677 offers unmatched convenience (oral dosing) and extensive human data, but its insulin sensitivity impairment is a significant limitation that has likely prevented regulatory approval. Ipamorelin offers the cleanest GH release profile of any secretagogue — no cortisol, no prolactin, no appetite stimulation, and no documented insulin effects — but requires injection and has less human data. For researchers prioritising metabolic safety and selective GH release, Ipamorelin is generally preferred. For those valuing convenience and sleep quality benefits, MK-677 has a unique profile.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MK-677 nor Ipamorelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.